With back-to-back PhI­II wins, Paci­ra guns for ex­pand­ed in­di­ca­tion for post-surgery pain drug Ex­par­el

Just weeks af­ter it an­nounced a Phase III win for its pain drug af­ter knee re­place­ment, Paci­ra Bio­Sciences has post­ed an­oth­er Phase III suc­cess in post-bunion surgery pain.

In this tri­al with 185 bunion surgery pa­tients, Ex­par­el sig­nif­i­cant­ly re­duced cu­mu­la­tive pain scores over a four-day pe­ri­od com­pared to bupi­va­caine. It al­so sig­nif­i­cant­ly re­duced post-surgery opi­oid use over the same pe­ri­od com­pared to bupi­va­caine — a key sec­ondary met­ric for pain drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER